Free tool
FAERS Monitor: Pemazyre
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213736 or its brand name (Pemazyre, Pemigatinib). Reports on generic versions are filed under their own applications.
Reports
853
Serious
532
62% of reports
Hospitalization
205
Death reported
150
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use155
- disease progression144
- death86
- fatigue82
- alopecia67
- cholangiocarcinoma62
- hyperphosphataemia54
- drug ineffective48
- diarrhoea46
- nausea43
- constipation40
- hospitalisation40
- decreased appetite37
- dry mouth35
- stomatitis35
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 101 |
| 2021 | 89 |
| 2022 | 66 |
| 2023 | 279 |
| 2024 | 123 |
| 2025 | 95 |
| 2026 | 100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cholangiocarcinomaSignal | 62 | 1071.6 | 838.5 | 62,539 |
| hyperphosphataemiaSignal | 54 | 635.3 | 489.0 | 32,726 |
| disease progressionSignal | 144 | 30.0 | 25.9 | 4,032 |
| stomatitisSignal | 35 | 14.2 | 10.3 | 419 |
| dry mouthSignal | 35 | 10.6 | 7.7 | 297 |
| alopeciaSignal | 67 | 8.4 | 6.7 | 434 |
| hospitalisationSignal | 40 | 6.4 | 4.7 | 179 |
| constipationSignal | 40 | 4.5 | 3.3 | 107 |
| off label useSignal | 155 | 4.4 | 3.8 | 416 |
| decreased appetiteSignal | 37 | 3.9 | 2.9 | 79 |
| fatigueSignal | 82 | 2.6 | 2.1 | 82 |
| deathSignal | 86 | 2.5 | 2.0 | 76 |
| diarrhoea | 46 | 1.8 | 1.3 | 15 |
| nausea | 43 | 1.3 | 1.0 | 4 |
| drug ineffective | 48 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.